Regulatory · Quality · Clinical Strategy
Regulatory strategy for products that don’t fit a standard playbook.
Atlas Bridge is a senior, founder-led advisory practice for complex life-science products — medtech, AI/SaMD, IVD/CDx, high-risk devices, digital health, and biopharma drug-development programs. If your product raises FDA or global pathway questions with no obvious answer, that’s the work we do.
Built for teams making high‑stakes regulatory decisions.
If your product is complex, novel, or sits between categories, you’re in the right place.
Medtech startups
Choosing a pathway, planning a first FDA interaction, or preparing a submission.
AI/SaMD & digital health companies
Keeping wellness and medical claims cleanly separated, and building a defensible route to market.
IVD/CDx & diagnostics developers
Aligning diagnostic strategy with the clinical programs it serves.
High-risk implantable & connected-device companies
Where evidence expectations are high and early strategy decisions have long-term consequences.
Biopharma teams
Drug-development regulatory strategy — Pre-IND/IND planning, 505(b)(2), and NDA/BLA strategy — and the questions where drugs meet devices, diagnostics, and digital health.
Investors & strategic partners
An independent read on regulatory risk before a deal.
International clinical research programs
Building clinical trial infrastructure designed for sponsor qualification and inspection readiness.
Strategy first. Then execution that matches it.
Most regulatory problems are strategy problems that surface later as documentation problems. We start with the decisions that shape everything downstream — intended use, claims, classification, pathway, evidence — then support the execution.
FDA Regulatory Strategy
Classification, claims architecture, pathway determination, and program-level planning for complex and hard-to-categorize products.
FDA Interactions & Submission Strategy
Pre-Sub planning, meeting strategy, and submission strategy built around how FDA evaluates products and the questions likely to matter.
SaMD/AI & Digital Health Strategy
Intended use and claims strategy, software documentation, change control, and phased commercialization for AI-enabled products.
IVD/CDx & Diagnostics Strategy
Diagnostic strategy from assay design through validation — including CDx programs that must stay in step with a therapeutic partner’s timeline.
Quality System & Inspection Readiness
Quality systems sized to your stage, audit preparation, and inspection-readiness assessment for companies and clinical sites.
Clinical‑Regulatory & Global Planning
Clinical-regulatory roadmaps, EU MDR/IVDR and international strategy, and trial site readiness for global programs.
Biopharma, Drug‑Development, and Combination‑Product Strategy
Atlas Bridge supports biopharma teams with drug-development regulatory strategy — Pre-IND/IND planning, FDA meeting strategy, 505(b)(2) pathway planning, and NDA/BLA submission strategy — with particular depth where drugs meet devices, diagnostics, and digital health: companion diagnostics, drug-device combinations, and combination products.
The role is strategic. We help clarify the regulatory pathway, FDA interaction strategy, submission architecture, and the cross-functional inputs — CMC, nonclinical, clinical, quality — needed to support a credible development plan.
Senior experience where products get complicated.
Hamid Idrissi Founder & Principal Consultant
Atlas Bridge was founded by Hamid Idrissi, Founder & Principal Consultant — a regulatory, quality, and clinical strategist with more than twenty years of experience across complex FDA-regulated product categories: Class III implantables, neuromodulation systems and implantable pulse generators, ICDs, AI/ML-based software, IVDs and companion diagnostics, and combination-product programs — along with FDA interactions, audits and inspections, EU MDR/IVDR, and international regulatory strategy. Atlas Bridge also provides drug-development regulatory strategy for biopharma teams — Pre-IND/IND planning, 505(b)(2), and NDA/BLA strategy — with particular depth where drugs intersect with devices, diagnostics, and digital health.
The practice is principal-led on purpose. When you work with Atlas Bridge, you work with Hamid — the same person who sets the strategy is the one in the room when it’s tested. No hand-offs, no juniors learning on your program.
And a commitment worth stating plainly: we don’t build arguments that sound good in a pitch and collapse in front of a reviewer. If a claim can’t be supported, we’ll tell you — and show you what can be.
20+ years
Regulatory, quality, and clinical strategy across FDA-regulated products
Class I–III
Including implantables, neuromodulation, and combination products
Devices · SaMD/AI · IVD/CDx · Biopharma & Drug Strategy
Including Pre-IND/IND, 505(b)(2), and NDA/BLA strategy, CDx, and drug-device and combination-product questions
US · EU · Global
FDA, EU MDR/IVDR, and international regulatory strategy
Structured around your decision, not billable hours.
Scope, deliverables, and fees are defined before work begins. Most engagements fit one of six models:
Strategic Advisory Retainer
Ongoing senior counsel: a defined monthly commitment for strategy questions, document review, and a regulatory voice in key discussions.
Regulatory Roadmap Package
A fixed-scope engagement producing your complete strategy: classification, pathway, claims, evidence plan, and sequencing.
FDA Interaction or Submission Strategy Package
Focused support for a specific FDA interaction or submission — from Q-Sub and Pre-IND through 510(k), De Novo, PMA, 505(b)(2), NDA, or BLA: strategy, gap assessment, and critical review before filing.
QMS / Inspection-Readiness Package
A structured assessment against the standard that matters, with findings ranked by consequence and a prioritized remediation plan.
Investor or Partner Diligence Package
An independent regulatory risk assessment for a transaction — on either side of the table.
International Clinical Trial Site-Readiness Package
Assessment and build-out support benchmarked against ICH GCP and FDA inspection expectations.
Not sure which fits? That’s normal — scoping the engagement correctly is part of the first conversation.
Start with a conversation, not a contract.
The best first step is an introductory consultation — a focused discussion of your product, your regulatory question, and whether we’re the right fit. No pitch, no obligation. Bring your hardest question; you’ll leave with a clearer picture of your options either way.
A few lines on these help us make the first call useful:
- Your product and stage of development
- The regulatory question or decision in front of you
- Any timeline driving it — a raise, a submission, an audit, a partnership
Write to Hamid Idrissi, Founder & Principal Consultant:
hamid@atlasbridgeregulatory.com Request an Introductory ConsultationWe respond to serious inquiries as promptly as possible. Atlas Bridge takes on a limited number of engagements at a time — if we’re not the right fit, we’ll say so, and where we can, point you to someone who is.